TRAVERE THERAPEUTICS

3611 Valley Centre Drive, Suite 300, San Diego, CA 92130

March 28, 2023

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Travere Therapeutics, Inc. is providing the report for the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The required information for the new product being launched is detailed below:

1. **Drug Product Description and Launch Information**

NDC	Product Name	Date Of Release into Commercial Market
68974-0200-30	Filspari (sparsentan) Oral tablets, 200mg, 30 tablets	2/28/2023
68974-0400-30	Filspari (sparsentan) Oral tablets, 400mg, 30 tablets	3/1/2023

2. **Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally**

   a. Our marketing and market access teams, supported by third-party agencies with rare disease experience, drives our commercialization and disease awareness efforts in the United States. Specifically, we implement a variety of industry accepted programs to educate physicians, including direct-to-physician contact by sales representatives, peer-to-peer educational programs, and participation in targeted medical convention programs. We plan to distribute FILSPARI through three direct to patient pharmacies, and operate Travere TotalCare, pursuant to which we will provide our comprehensive patient support services. This patient support program for FILSPARI in the United States will provide services, assistance and resources that will help patients understand IgAN, manage the insurance process, fill their prescriptions and initiate treatment. Travere has a long-standing commitment to setting prices responsibly based on the value our medicines

bring to patients, society and healthcare systems. Our approach reflects our commitment to continued transparency in how we price our prescription medicines in the United States while minimizing our contribution to health system spending.

When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes consultation with external stakeholders and considers the following factors:

i. Clinical value and outcomes, or the benefit the medicine delivers to patients, and how well it works compared to a standard of care;
ii. Economic value, or how the medicine reduces the need—and therefore costs—of other healthcare interventions
iii. Social value, or how the medicine contributes to quality of life, and productivity.

3. **Estimated volume of patients who may be prescribed the drug**
    a. 1500
4. **Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval**
    a. FDA priority review granted.
5. **Date and price of acquisition if the drug was not developed by the manufacturer**
    a. This product was not acquired.

Sincerely,

Sayan Das Mitra
Senior Director, Market Access, Pricing and Contracts
+1-650-255-7887
Sayan.mitra@travere.com